Why did 1AD.AX stock fall today?

1AD.AX stock fell due to heavy selling ahead of clinical and funding uncertainty; volume spiked to **11,005,191** shares and the stock closed at **A$0.005**, reflecting re‑pricing of near‑term risk.

What is Meyka AI’s short‑term forecast for 1AD.AX stock?

Meyka AI's forecast model projects **A$0.01** over the next month for 1AD.AX stock, implying about **100.00%** upside from **A$0.005**. Forecasts are model‑based projections and not guarantees.

What are the key risks for investors in 1AD.AX stock?

Key risks include clinical trial setbacks, dilution from capital raises, limited cash per share **A$0.00946**, and small market cap **A$783,356.00** that increases volatility and liquidity risk for 1AD.AX stock.

Where can I find official company information on 1AD.AX stock?

Company disclosures and programme details are on AdAlta’s website and social channels. See company site [AdAlta Limited](https://adalta.com.au) and the company Twitter [AdAlta](https://twitter.com/AdAlta1AD) for updates.

AU Stocks

1AD.AX AdAlta Limited ASX down 28% on close 21 Jan 2026: clinical readout risk

ByHuzaifa Zahoor January 21, 2026January 21, 2026

The 1AD.AX stock fell sharply at market close on 21 Jan 2026, sliding 28.57% to A$0.005 on heavy volume of 11,005,191 shares as investors reacted to clinical timing and funding uncertainty. This sell‑off makes 1AD.AX one of today’s top losers on the ASX healthcare list. The move followed no company release but reflects stretched valuation, negative EPS of -0.01, and a year low near A$0.002, increasing near‑term volatility for holders and traders in the Australian biotechnology sector.